Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with bevacizumab (SARC016)

Authors

Brigitte C. Widemann, National Cancer Institute
Anglea C. Hirbe, Washington University School of Medicine in St. Louis
et al

Journal

Sarcoma

Publication Date

7-24-2019

Volume

2019

First Page

7656747

Document Type

Open Access Publication

DOI

10.1155/2019/7656747

Rights and Permissions

Brigitte C. Widemann, Yao Lu, Denise Reinke, et al., "Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)," Sarcoma, vol. 2019, Article ID 7656747, 8 pages, 2019. DOI: 10.1155/2019/7656747 Copyright © 2019 Brigitte C. Widemann et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Widemann, Brigitte C.; Hirbe, Anglea C.; and et al, "Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with bevacizumab (SARC016)." Sarcoma. 2019, 7656747 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11091